E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Non-neurogenic Overactive Bladder (OAB) |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10059617 |
E.1.2 | Term | Overactive bladder |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To quantify the action of botulinum toxin serotype-A (BOTOX) on urgency using a novel electronic measurement device. |
|
E.2.2 | Secondary objectives of the trial |
To quantify the action of botulinum toxin serotype-A (BOTOX) on a number of secondary end-points including quality of life, urinary frequency and voided volume and urodynamic parameters measured using ambulatory urodynamics. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Previous use of botulinum toxin Type A
Outpatient, male or female subjects, of any race, between 21 and 75 years of age.
Subjects with a non-neurogenic bladder and detrusor overactivity
Subjects with urinary incontinence (minimum of one occurrence per day). [NOTE: Bladder emptying may be accomplished with straining, intermittent catheterization (IC), spontaneous micturition or leakage episodes.]
Subject has urge urinary incontinence on 3 day bladder diary as defined by urinary leakage associated with common triggers of urge leakage such as “key in the door”, running to the bathroom, standing up, running water, etc.
Subject has severe incontinence as defined below: 1) Mean # of daily leakage episodes ≥ 1/day documented on 3 day bladder diary 2) Mean # of voids ≥ 8/day documented on 3 day bladder diary
Laboratory findings required 1)Urine dipstick or urine culture negative for urinary tract infection 2)Post void residual volume <150 cc
Ability to follow study instructions and likely to complete all required visits
A willingness and ability to perform intermittent clean catheterization
Subjects able to understand the requirements of the study, including completing questionnaires and signing Informed Consent
|
|
E.4 | Principal exclusion criteria |
Patients not previously exposed to botulinum toxin type A
Use of botulinum toxin type A within previous 6 months
Female subjects who are pregnant (positive urine pregnancy test) or of childbearing age who are not taking suitable contraceptive precautions.
Subjects with a history of transurethral sphincterotomy, bladder neck or prostatic resection, previous bladder surgery including myomectomy or augmentation cystoplasty.
Subjects with chronic indwelling catheters.
Subjects with any medical condition that may increase their risk of exposure to botulinum toxin including diagnosed myasthenia gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis or any other disease that might interfere with neuromuscular function.
Subjects with an allergy or sensitivity to any component of BOTOX®
Subjects unable to discontinue any agents that might interfere with neuromuscular function (i.e., aminoglycoside antibiotics, curare-like agents, etc.).
Subjects with, in the opinion of the Investigator, unstable multiple sclerosis.
Subjects with known, uncontrolled systemic disease.
Subjects with evidence of recent alcohol/drug abuse.
Subjects who, in the opinion of the Investigator, have a significant condition or situation that may put the subject at significant risk, confound the study results, or interfere significantly with the subject's participation in the study.
Subjects with a history of poor cooperation, non-compliance, or unreliability.
Subjects currently participating in an investigational drug study or who have participated in an investigational drug study within 30 days of the Baseline Visit.
History of carcinoma of the bladder
Presence of a foreign body in the bladder, cystitis or other correctable aetiology for urgency urinary incontinence.
Gross fecal incontinence (due to confounding effects on pad weights and counts)
Clear evidence of emptying phase or detrusor dysfunction that may put the subject at risk for urinary retention
Known allergy to Ciprofloxacin (used for urinary tract infection prophylaxis) or to lidocaine or related compounds (used for local analgesia)
Prior documented resistance to Botox®
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
a)We hypothesise that Botox® will significantly decrease the frequency of urgency and increase the warning time, refractory (urgency free) time and intervoid interval (primary end points). b)We Hypothesise that Botox® will cause statistically significant alterations in urinary frequency, voided volume and quality of life (secondary end points). c)We Hypothesise that Botox® will decrease the duration, amplitude and frequency of overactive detrusor contractions measured on ambulatory urodynamics (secondary end points).
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Close out visit for patients will be 6 months post treatment |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |